CMEABIM MOC

PCSK9 Inhibitors in Patients With Diabetes: A Closer Look at CV Risk Reduction

PCSK9 Inhibitors in Patients With Diabetes: A Closer Look at CV Risk Reduction

This activity is supported by an educational grant from Amgen.

Overview

CME Information

page 1 of 8